In vivo studies revealed that D1(A12), a cross-domain antibody that binds to both the M and D+C domains of ADAM17, was effective in reducing the tumour burden in mice with IGROV1-Luc tumours [139,140]. This evidence concerns the gene ADAM17 and neoplasm.